OBJECTIVE: The purpose of the study was to examine the relationship between gastric emptying and the efficacy of an alpha-glucosidase inhibitor in @entity2175 @entity1 . RESEARCH DESIGN AND METHODS: Sixteen @entity2175 @entity1 (4 @entity1 treated with diet therapy alone and 12 receiving a @entity4136 ) were given 0.6 mg of @entity54587 daily for 4 weeks. The efficacy of @entity54587 was assessed by measurement of HbA1c, fasting plasma @entity413 , and 45- and 120-min postprandial plasma @entity413 (PPG) and serum insulin concentrations before and after the 4 weeks of @entity54587 therapy. Gastric emptying was evaluated using the proportional cumulative area under the absorption curve (% AUC) of plasma @entity1443 concentration at 60 min after ingestion of a liquid test meal containing 20 mg/kg of @entity1443 . These measurements were also taken before and after the therapy. RESULTS: The change in the 45-min PPG levels from the fasting state correlated significantly with the % AUC of the plasma @entity1443 concentrations (r = 0.625, P = 0.0096) before the @entity54587 administrations. The mean 45-min and 2-h PPG levels were reduced significantly after 4 weeks of @entity54587 (P < 0.05 and P < 0.01, respectively). Two-hour postprandial serum insulin concentrations were also significantly reduced at the end of the treatment period (P < 0.05). The changes in the PPG levels between pre- and posttreatment periods correlated significantly with the % AUC of the plasma @entity1443 concentrations before the treatment period (r = 0.499, P = 0.0490; r = 0.713, P = 0.0019, respectively). There was no significant difference in the plasma @entity1443 concentrations between pre- and posttreatment periods. CONCLUSIONS: The rate of gastric emptying affects the efficacy of @entity54587 therapy in @entity2175 @entity1 . @entity54587 did not however alter the rate of gastric emptying.

Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in XXXX @entity1 .

@entity2175 :: ('MESH:D003924', 'Disease') :: ['NIDDM'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity4136 :: ('CHEBI:26831', 'Chemical') :: ['sulfonylurea'] @entity1443 :: ('MESH:D000082', 'Chemical') :: ['acetaminophen'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity54587 :: ('MESH:C102817', 'Chemical') :: ['Voglibose', 'voglibose']
@entity2175 :: (MESH:D003924,Disease) :: ['NIDDM']
